Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Douglas Johnson

10 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    VICCMEL15137

    07/21/2015

    Characterizing the Cardiometabolic Implications of Immune Therapy

    Basic Science

    VICCMEL09109

    06/03/2010

    Storage and Research Use of Human Biospecimens from Melanoma Patients and Clinical Testing for the Assignment of Therapy

    Other

    VICCMEL14103

    08/17/2015

    A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials

    Other

    VICCMEL15138

    06/23/2015

    Survivorship in Patients Receiving Immune Checkpoint Inhibitors

    Treatment

    VICCMD15107

    11/07/2017

    A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

    Treatment

    VICCMEL16138

    09/08/2017

    A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma

    Treatment

    VICCMD1636

    12/21/2016

    A Phase 1b/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

    Treatment

    VICCMD1649

    12/14/2016

    A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer

    Treatment

    VICCMEL1471

    02/04/2015

    A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma

    Treatment

    VICCMEL1457

    01/19/2015

    A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations


    Print this page for your doctor